Global Psoriasis Therapeutics Market
DUBLIN, April 9, 2014 /PRNewswire/ –
Research and Markets (
http://www.researchandmarkets.com/research/stldww/global_psoriasis) has announced the
addition of the “Global Psoriasis Therapeutics Market”
[http://www.researchandmarkets.com/research/stldww/global_psoriasis ] report to their
The analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of
4.06 percent over the period 2012-2016. One of the key factors contributing to this market
growth is the increasing uptake of biologics. The Global Psoriasis Therapeutics market has
also been witnessing an increased focus on using combination therapies for treating
psoriasis. However, the adverse side effects associated with psoriatic drugs could pose a
challenge to the growth of this market.
The report, the Global Psoriasis Therapeutics Market, has been prepared based on an
in-depth market analysis with inputs from industry experts. The report covers the market
in the Americas, and the EMEA and APAC regions; it also covers the Global Psoriasis
Therapeutics market landscape and its growth prospects in the coming years. The report
also includes a discussion of the key vendors operating in this market.
One of the main trends witnessed in the Global Psoriasis
[http://www.researchandmarkets.com/research/stldww/global_psoriasis ] Therapeutics market
is the increased focus on combination therapies. A current trend witnessed in the Global
Psoriasis Therapeutics market is the use of combination therapies for treating psoriasis.
Light therapy along with topical treatment products are generally used in combination for
the treatment of mild to moderate level of psoriasis. For severe psoriasis oral or
injected drugs are used.
Due to the severe side effects of these drugs, combination of therapies is used for
the effective treatment of severe psoriasis. When the disease is more severe, topic
therapy products such as cream is used in combination with oral medications or light
therapy. For instance, Anthralin
[http://www.researchandmarkets.com/research/stldww/global_psoriasis ] is sometimes used in
combination with UV light. Light therapy is also used sometimes in combination with
medications. Moreover, in Goeckerman therapy UVB treatment and coal tar treatment is used
together as it is more effective than single therapy.
According to the report, one of the main factors driving the market is the increasing
uptake of biologics. In recent years the enhanced understanding of the molecular basis
underlying psoriasis has led to the introduction of biological drugs, providing a new
effective treatment option for this disease. Biologics aim key steps in the pathogenesis
of psoriasis and can be categorized into three main categories: TNF alpha inhibitors, T
cell inhibitors, and IL-12/IL-23 inhibitors.
Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Types of Psoriasis 7. Market Landscape 8. Geographical Segmentation 9. Rate of Incidence and Prevalence 10. Pipeline Analysis 11. Vendor Landscape 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Key Vendor Analysis 19. Other Reports in this Series
- Abbvie Inc. - Amgen Inc. - AstraZeneca plc - Bristol Myers Squibb Co. - Celgene Corp. - Eisai Co. Ltd. - Eli Lilly and Co. - GlaxoSmithKline plc - Incyte Corp. - Isotechnika Inc. - Janssen Biotech Inc. - LEO Pharma A/S - Merck & Co. Inc. - Novartis International AG - Pfizer Inc. - UCB S.A
For more information visit
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets